Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7 Tumor-Agnostic 2 Thoracic 1 Breast 1

Conditions

Recurrence 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 542 Pemetrexed 392 pembrolizumab 372 Cisplatin 356 Paclitaxel 285 Docetaxel 240 Gemcitabine 168 Nivolumab 158 Erlotinib Hydrochloride 147 Bevacizumab 114 atezolizumab 104 osimertinib 99 durvalumab 92 Etoposide 90 Gefitinib 68 130-nm albumin-bound paclitaxel 65 Cetuximab 64 Ipilimumab 60 Drug Therapy 51 Topotecan 48 Injections 44 Afatinib 41 tislelizumab 40 Cyclophosphamide 39 Albumin-Bound Paclitaxel 37 Vinorelbine 36 Crizotinib 34 cemiplimab 31 icotinib 26 Radiotherapy 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × PEGPH20 × Thoracic × Clear all

NCT02346370 2019-02-08

PRIMAL

Halozyme Therapeutics

Phase 1 Terminated

16 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡